MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
LogicBio Therapeutics Cash Conversion Cycle 2011-2026 | LOGC
Annual Cash Conversion Cycle LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.88 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.88 | 9.88 | 9.88 |
Quarterly Cash Conversion Cycle LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 0.49 | - | 4.22 | 9.44 | 34.8 | - | 25.9 | 24.9 | 11.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.8 | 0.49 | 15.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 309.66 | -3.27 % | $ 40.6 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 22.88 | 4.91 % | $ 1.07 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.41 | 4.07 % | $ 363 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.32 | 1.41 % | $ 462 M | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.53 | 1.41 % | $ 3.12 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 54.64 | 1.0 % | $ 10.5 B | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.6 | -0.62 % | $ 426 M | Britain |
 |
BioXcel Therapeutics
BTAI
|
-32.5 K | $ 1.15 | 7.48 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
-51.6 | - | -0.88 % | $ 598 M | USA |